<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-HQ4H3WJX/8f1d915a-31c5-40b4-8336-ae0e104d4a71/HTML"><dcterms:extent>26 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-HQ4H3WJX/8b45c30d-d025-477d-a9da-2556d27a80f7/PDF"><dcterms:extent>571 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-HQ4H3WJX/94f1b689-8e99-4670-9fc7-3e08e34478ae/TEXT"><dcterms:extent>23 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1992-2025"><edm:begin xml:lang="en">1992</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:DOC-HQ4H3WJX"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S" /><dcterms:issued>2011</dcterms:issued><dc:creator>Adell, Gunnar</dc:creator><dc:creator>Gao, Jinfang</dc:creator><dc:creator>Lewander, Andreas</dc:creator><dc:creator>Sun, Xiao-Feng</dc:creator><dc:creator>Zhang, Hong</dc:creator><dc:format xml:lang="sl">številka:4</dc:format><dc:format xml:lang="sl">letnik:45</dc:format><dc:format xml:lang="sl">str. 279-284, III</dc:format><dc:identifier>ISSN:1318-2099</dc:identifier><dc:identifier>COBISSID:29635289</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-HQ4H3WJX</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Association of Radiology and Oncology</dc:publisher><dcterms:isPartOf xml:lang="sl">Radiology and oncology (Ljubljana)</dcterms:isPartOf><dc:subject xml:lang="sl">Fosfoserin</dc:subject><dc:subject xml:lang="en">Gene Expression</dc:subject><dc:subject xml:lang="sl">Gensko izražanje</dc:subject><dc:subject xml:lang="en">Immunohistochemistry</dc:subject><dc:subject xml:lang="sl">Imunohistokemija</dc:subject><dc:subject xml:lang="sl">Limfatična metastaza</dc:subject><dc:subject xml:lang="en">Lymphatic Metastasis</dc:subject><dc:subject xml:lang="sl">NF-kapa B</dc:subject><dc:subject xml:lang="sl">Nf-Kappa B</dc:subject><dc:subject xml:lang="en">Pathology</dc:subject><dc:subject xml:lang="en">Phosphoserine</dc:subject><dc:subject xml:lang="en">Radiotherapy</dc:subject><dc:subject xml:lang="en">Rectal Neoplasms</dc:subject><dc:subject xml:lang="sl">Rektalne novotvorbe</dc:subject><dc:subject xml:lang="en">Tumor Markers, Biological</dc:subject><dc:subject xml:lang="sl">Tumorski označevalci biološki</dc:subject><dcterms:temporal rdf:resource="1992-2025" /><dc:title xml:lang="sl">Expression of NF-kB p65 phosphorylated at serine-536 in rectal cancer with or without preoperative radiotherapy|</dc:title><dc:description xml:lang="sl">Background. In the present study, we investigated NF-eB p65 phosphorylated at Serine-536 (phosphor-Ser536-p65) in rectal cancer and its relationship to preoperative radiotherapy (RT), clinicopathological variables and biological factors.Patients and methods. Expression of phosphor-Ser536-p65 was examined by using immunohistochemistry in 141primary rectal cancers, 149 normal mucosa specimens and 48 metastases in the lymph nodes, from rectal cancer patients who participated in a Swedish clinical trial of preoperative RT. Results. The expression of phosphor-Ser536-p65 in the cytoplasm increased from normal mucosa to primary tumour (p&lt;0.0001, for both the group that did and the group that did not received RT). The expression did not further increase from primary tumour to metastasis in either group (p&gt;0.05). Expression of phosphor-Ser536-p65 was positively related to, or tended to be related to, theexpression of tumour endothelium marker 1 (TEM1, p=0.02), FXYD-3 (p=0.001),phosphatase of regenerating liver (PRL, p=0.02), p73 (p=0.048) and meningioma associated protein (MAC30, p=0.05) in the group that received RT but there were no such relationships in the group that did not received RT (p&gt;0.05). The expression of phosphor-Ser536-p65 was not related to clinicopathological factors including survival (p&gt;0.05). Conclusions. The increased expression of phosphor-Ser536-p65 may be involved in rectal cancer development. After RT, phosphor-Ser536-p65 seems to be positively related to the biological factors, which associated with more malignant features of tumours. However, phosphor-Ser536-p65 was not directly related to the responseof RT based on recurrence and survival</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:DOC-HQ4H3WJX"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:DOC-HQ4H3WJX" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:DOC-HQ4H3WJX/8b45c30d-d025-477d-a9da-2556d27a80f7/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Društvo radiologije in onkologije</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:DOC-HQ4H3WJX/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:DOC-HQ4H3WJX" /></ore:Aggregation></rdf:RDF>